Luminal A and B1 | Luminal B2 | Total | Age | Luminal A and B1 | Luminal B2 | Total | |
---|---|---|---|---|---|---|---|
Distribution of breast cancer patients with positive receptors according to HER2 and age | |||||||
ER+PgR+ | 666 | 172 | 838 | <55 | 218 | 69 | 287 |
ER+PgR− | 66 | 38 | 104 | >54 | 525 | 141 | 666 |
ER−PgR+ | 11 | 0 | 11 | Total | 743 | 210 | 953 |
Total | 743 | 210 | 953 | ||||
Χ2 (p) | 13.70 (0.0002) | Χ2(p) | 2.34 (0.1260) | ||||
Distribution of ductal breast cancer patients according to their steroid receptor phenotype and Ki-67 value | |||||||
ER+ tumors without HER2 | Luminal A (Ki-67 < =14%) | Luminal B1 (Ki-67 > 14%) | Total | Luminal B2 | Ki-67 < =14% | Ki-67 > 14% | Total |
ER+PgR+ | 365 | 301 | 666 | ER+PgR+ | 49 | 123 | 172 |
ER+PgR− | 26 | 40 | 66 | ER+PgR− | 9 | 29 | 38 |
ER−PgR+ | 6 | 5 | 11 | ER−PgR+ | 0 | 0 | 0 |
Total | 397 | 346 | 743 | Total | 58 | 152 | 210 |
Χ2(p) | 5.73 (0.0167) | Χ2 (p) | 0.36 (0.5489) | ||||
Distribution of ductal breast cancer patients according to their age and other features | |||||||
Age of Luminal A patients | ER+PgR+ | ER+PgR− | ER−PgR+ | Age of HER2 patients | Ki-67 < =14% | Ki-67 > 14% | Total |
<55 | 99 | 5 | 4 | <55 | 3 | 38 | 41 |
>54 | 266 | 21 | 2 | >54 | 16 | 78 | 94 |
Total | 365 | 26 | 6 | Total | 19 | 116 | 135 |
Χ2(p) | 0.77 (0.3789) | Χ2 (p) | 2.22 (0.1360) | ||||
Age of Luminal B1 patients | ER+PgR+ | ER+PgR− | ER−PgR+ | Age of triple-negative patients | Ki-67 < =14% | Ki-67 > 14% | Total |
<55 | 103 | 6 | 1 | <55 | 7 | 68 | 75 |
>54 | 198 | 34 | 4 | >54 | 14 | 71 | 85 |
Total | 301 | 40 | 5 | Total | 21 | 139 | 160 |
Χ2(p) | 6.00 (0.0143) | Χ2 (p) | 1.78 (0.1822) | ||||
Age of Luminal B2 patients | ER+PgR+ | ER+PgR− | ER−PgR+ | Age of patients | triple-negative | HER2 | Total |
<55 | 65 | 4 | 0 | <55 | 75 | 41 | 116 |
>54 | 107 | 34 | 0 | >54 | 85 | 94 | 179 |
Total | 172 | 38 | 0 | Total | 160 | 135 | 295 |
Χ2(p) | 10.49 (0.0012) | Χ2 (p) | 8.36 (0.0038) |